Jason Grebely, Gregory J Dore, Frederick L Altice, Brian Conway, Alain H Litwin, Brianna L Norton, Olav Dalgard, Edward J Gane, Oren Shibolet, Ronald Nahass, Anne F Luetkemeyer, Cheng-Yuan Peng, David Iser, Isaias Noel Gendrano, Michelle M Kelly, Peggy Hwang, Ernest Asante-Appiah, Barbara A Haber, Eliav Barr, Michael N Robertson, Heather Platt
BACKGROUND: Hepatitis C virus (HCV) reinfection after successful treatment may reduce the benefits of cure among people who inject drugs. OBJECTIVE: To evaluate the rate of HCV reinfection for 3 years after successful treatment among people receiving opioid agonist therapy (OAT). DESIGN: A 3-year, long-term, extension study of persons enrolled in the CO-STAR (Hepatitis C Patients on Opioid Substitution Therapy Antiviral Response) study (ClinicalTrials...
August 9, 2022: Annals of Internal Medicine